Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Hexal
RAMIPRIL HEXAL SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): RAMIPRIL HEXAL Ramipril HEXAL™1.25 mg tablets Ramipril HEXAL™ 2,5 mg tablets Ramipril HEXAL™ 5 mg tablets COMPOSITION Ramipril HEXAL 1,25 mg tablets: 1.25 mg ramipril as active substance Ramipril HEXAL 2,5 mg tablets: 2.5 mg ramipril as active substance Ramipril HEXAL 5 mg tablets: 5 mg ramipril as active substance PHARMACOLOGICAL CLASSIFICATION A 7.1.3 Other hypotensives PHARMACOLOGICAL ACTION Ramipril HEXAL inhibits angiotensin converting enzyme (ACE) activity. It inhibits the conversion of the relatively inactive angiotensin I to the active angiotensin II. Angiotensin II is a potent vasoconstrictor and stimulates the release of aldosterone. Decreased angiotensin II levels result in a decrease in vasopressor activity and a reduction in aldosterone secretion, which may result in small increases in serum potassium. Ramipril is a prodrug, which is hydrolyzed in the liver after absorption from the gastrointestinal tract to form the active angiotensin converting enzyme inhibitor, ramipralat. It is also thought that ACE inhibition may inhibit degradation of bradykinin, leading to increased bradykinin levels. Pharmacokinetics The extent of absorption after oral administration is estimated to be 30% to 60% with wide variability between patients. The plasma half-life is 13 to 17 hours for ramiprilat for 5 to 10 mg ramipril doses, and several times longer for lower doses such as 1.25 mg to 2.5 mg, which is increased in renal impairment. The time to achieve peak serum concentration is within 1 hour and 2 to 4 hours for ramiprilat. Ramipril is renally eliminated and excreted 100% unchanged in the urine. INDICATIONS • Mild to moderate hypertension. • Cardiac failure following myocardial infarction. Read the complete document